Description: Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Home Page: www.siegfried.ch
Untere Bruehlstrasse 4
Zofingen,
4800
Switzerland
Phone:
41 62 746 1111
Officers
| Name | Title |
|---|---|
| Dr. Wolfgang Wienand Ph.D. | Chief Exec. Officer |
| Dr. Reto Suter Ph.D. | Chief Financial Officer |
| Dr. Jurgen Roos Ph.D. | Chief Scientific Officer |
| Mr. Peter Kiechle Ph.D. | Chief Compliance Officer |
| Dr. Luca Dalla Torre | Gen. Counsel & Sec. |
| Mr. Peter A. Gehler | Chief Communications Officer |
| Mr. Arnoud Michael Middel | Chief HR Officer |
| Ms. Marianne Spane | Chief Bus. Officer |
| Mr. Enno Schweinberger Ph.D. | Head Global Quality Management DS - Zofingen |
| Daniel Nieper | Chief Strategy Officer |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 22.0751 |
|---|---|
| Trailing PE: | 22.17 |
| Price-to-Book MRQ: | 3.7591 |
| Price-to-Sales TTM: | 2.1645 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3511 |